2.1. Study Design, Patients, and Procedures
NSCLC, tumor, Blood tumor, Tumors, IIIB-IV
DISEASE PROGRESSION, TUMOR, BLOOD TUMOR, TUMORS, ADVERSE EVENT, NSCLC
This trial was a single-arm, prospective, multi-center cohort study and involved the collection of blood samples from patients receiving atezolizumab. The name ‘BUDDY’ derived from the phrase “evaluation of Blood tumor mUtation burDen for improveD efficacY of atezolizumab”. Between December 2019 and April 2021, patients with locally advanced or metastatic (IIIB-IV or relapsed) NSCLC were recruited from six tertiary centers in South Korea. Patients with NSCLC who had previously received one or two chemotherapy regimens, including at least one platinum-based regimen, were enrolled in this study. The inclusion and exclusion criteria are described in Patients received 1200 mg of atezolizumab intravenously every three weeks. The treatment continued until the patient experienced a serious adverse event, lost clinical benefit, had confirmed disease progression or withdrew informed consent. Computed tomography (CT) was performed to analyze the tumor at the baseline and every three cycles after that. Clinical responses to the treatment were defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [